ACRS - CIK 0001557746
Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.83M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $7.83M | -58.2% |
| FY 2024 | $18.72M | -40.1% |
| FY 2023 | $31.25M | +5.0% |
| FY 2022 | $29.75M | +340.1% |
| FY 2021 | $6.76M | +4.3% |
| FY 2020 | $6.48M | +53.3% |
| FY 2019 | $4.23M | -31.3% |
| FY 2018 | $6.15M | +265.5% |
| FY 2017 |
Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.83M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Aclaris Therapeutics, Inc.'s revenue grew from $1.68M to $7.83M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.68M |
| - |